Authors
Kim-Ngan Huynh Lam, Hen Huu Phan, Sam Minh Thai, Minh Duc Do
Published in
Medicine. Volume 105. Issue 42. Pages e51216. Oct 16, 2026.
Abstract
Hyperparathyroidism (HPT) may persist in patients after kidney transplantation (KT). A better understanding of which patients are likely to have persistent HPT after KT would help in the development of optimal management strategies. Our aim was to examine the prevalence of persistent HPT after KT in a contemporary cohort and to identify risk factors associated with persistent HPT at 6 months. We followed 104 KT subjects in a longitudinal prospective cohort at Cho Ray Hospital, Vietnam, from October 2023 to May 2025. Persistent HPT was defined as a parathyroid hormone (PTH) level of 150 pg/mL at 6 months after KT. Among the 104 patients, the prevalence of persistent HPT at 6 months was 58.65%. The average PTH levels pretransplant and at 6 months posttransplant were 375.70 (IQR = 259.00-603.25) pg/mL and 167.95 (IQR = 112.53-227.30) pg/mL, respectively. Patients with persistent HPT had significantly higher baseline PTH (median 489 vs 273, P < .001) and alkaline phosphatase levels (median 102.0 vs 89.5, P = .025), and also experienced longer durations of chronic kidney disease (median 5.0 vs 2.0, P = .007) and dialysis therapy (2.0 vs 1.0, P < .001). Higher pretransplant intact PTH was independently associated with persistent HPT across both multivariable models, whereas the association with dialysis duration was significant only when categorized as ≥1 year. Our findings suggest that high pretransplant intact PTH independently predicts persistent HPT at 6 months, whereas dialysis duration is only significant when it reaches 1 year or longer.
PMID:
42888627
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0